Jane Street Group, LLC Altimmune, Inc. Put Options Transaction History

Jane Street Group, LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$5.5 - $8.1 $268,400 - $395,280	48,800 New	48,800 $299,000
Q4 2021 Feb 15, 2022	SELL	$8.69 - $12.48 $130,349 - $187,200	-15,000 Reduced 23.4%	49,100 $450,000
Q3 2021 Nov 16, 2021	SELL	$8.43 - $16.81 $306,009 - $610,203	-36,300 Reduced 36.16%	64,100 $725,000
Q2 2021 Aug 16, 2021	BUY	$9.85 - $16.46 $167,450 - $279,820	17,000 Added 20.38%	100,400 $989,000
Q1 2021 May 18, 2021	BUY	$12.71 - $24.31 $78,802 - $150,722	6,200 Added 8.03%	83,400 $1.18 Million
Q4 2020 Feb 17, 2021	BUY	$7.84 - $14.22 $605,248 - $1.1 Million	77,200 New	77,200 $871,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $426M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.